This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange fell a fraction to 998.71 Tuesday. Pat DiCapo's halted capital pool shell, POCML 2 Corp. (PCC), has filed its much-anticipated filing statement outlining the details of its qualifying transaction with Bedrocan Canada Inc., a licensed producer of medical marijuana under Health Canada's new Marihuana for Medical Purposes Regulations (MMPR) policy. Later this month, possibly even next week, the shell will roll back its shares 1:2, complete its acquisition of the medical marijuana producer and resume trading as Bedrocan Cannabis Corp.

After POCML 2 rolls back its shares 1:2, leaving it with three million postconsolidated shares, it will issue 64.5 million postconsolidated shares to Bedrocan shareholders. The target received its production licence from Health Canada last December, becoming the fourth applicant to receive a licence. Today, there are 13 licensed producers and hundreds of hopefuls that have filed applications with the government. For now, Bedrocan Canada imports its medical marijuana from its joint venturer, Bedrocan BV, the government-appointed sole supplier of medical marijuana to pharmacies in the Netherlands, where since 2011 patients have been able to purchase their product with health insurance. Bedrocan BV, managed by Tjalling Erkelens, also sends its product to Germany, Italy, Finland and Norway, and it expects to supply Switzerland and the Czech Republic later this year.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS